MARKET

AKRO

AKRO

Akero
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.33
+0.96
+3.64%
After Hours: 27.33 0 0.00% 16:00 05/07 EDT
OPEN
26.70
PREV CLOSE
26.37
HIGH
27.73
LOW
26.70
VOLUME
105.33K
TURNOVER
--
52 WEEK HIGH
41.16
52 WEEK LOW
19.58
MARKET CAP
951.64M
P/E (TTM)
-11.0684
1D
5D
1M
3M
1Y
5Y
BRIEF-Akero Therapeutics Appoints Yuan Xu To Its Board Of Directors
reuters.com · 04/26 12:45
89bio could close the valuation gap with Akero by end of 2021: Cantor
89bio ([[ETNB]] +6.9%) has surged today after Cantor Fitzgerald initiated coverage on the stock with an overweight rating and the price target at $58.00 per share implies as much as
Seekingalpha · 04/21 16:38
Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the first pat...
GlobeNewswire · 03/23 13:00
DJ Akero Therapeutics Price Target Cut to $63.00/Share From $70.00 by Morgan Stanley
Dow Jones · 03/23 11:58
DJ Akero Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 03/23 11:58
Morgan Stanley Maintains Overweight on Akero Therapeutics, Lowers Price Target to $63
Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Overweight and lowers the price target from $70 to $63.
Benzinga · 03/23 11:48
DJ Akero Therapeutics Price Target Raised to $68.00/Share From $61.00 by HC Wainwright & Co.
Dow Jones · 03/23 11:14
DJ Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/23 11:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKRO. Analyze the recent business situations of Akero through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKRO stock price target is 60.71 with a high estimate of 81.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 121
Institutional Holdings: 36.99M
% Owned: 106.23%
Shares Outstanding: 34.82M
TypeInstitutionsShares
Increased
38
2.54M
New
8
154.17K
Decreased
24
467.25K
Sold Out
16
365.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman/Independent Director
Mark Iwicki
President/Chief Executive Officer/Director
Andrew Cheng
Co-Founder/Chief Operating Officer/Executive Vice President
Jonathan Young
Co-Founder/Chief Scientific Officer
Timothy Rolph
Chief Financial Officer/Executive Vice President
William White
Other
Kitty Yale
Independent Director
Tomas Heyman
Independent Director
Yuan Xu
Non-Executive Independent Director
Kevin Bitterman
Non-Executive Independent Director
Seth Harrison
Non-Executive Independent Director
Jane Henderson
Non-Executive Independent Director
Graham Walmsley
No Data
About AKRO
Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. Its lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, with the potential to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).

Webull offers kinds of Akero Therapeutics Inc stock information, including NASDAQ:AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.